BMS-202
BMS-202 is a potent and nonpeptidic PD-1/PD-L1 complex inhibitor with an IC50 of 18 nM and a KD of 8 μM. BMS-202 binds to PD-L1 and blocks human PD-1/PD-L1 interaction. BMS-202 has antitumor activity[1][2].
Product Specifications
CAS Number
1675203-84-5
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Apoptosis; PD-1/PD-L1
Type
Reference compound
Related Pathways
Apoptosis; Immunology/Inflammation
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/BMS-202.html
Purity
99.48
Solubility
DMSO : ≥ 100 mg/mL
Smiles
CC(NCCNCC1=CC=C(OCC2=C(C)C(C3=CC=CC=C3)=CC=C2)N=C1OC)=O
Molecular Formula
C25H29N3O3
Molecular Weight
419.52
Precautions
H302, H315, H319, H335
References & Citations
[1]Zak KM, et al. Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1) . Oncotarget. 2016 May 24;7 (21) :30323-35.|[2]Ashizawa T, et al. Antitumor activity of the PD-1/PD-L1 binding inhibitor BMS-202 in the humanized MHC-double knockout NOG mouse. Biomed Res. 2019;40 (6) :243-250.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNCB2783-100 1x 100 µL
C1QA / Complement C1q A-Chain (C1QA/2783), Biotin conjugate, 0.1mg/mL
Sign In for Pricing
View Details 